Examining the Complexities of Addiction Recovery and Treatment Risks

The death of Presley Gerber at 27 has brought attention to the risks of overdose, complications from withdrawal, and the hurdles in addiction recovery. Gerber, son of Cindy Crawford and Rande Gerber, passed away at a rehabilitation facility in California, as per Los Angeles County Medical Examiner’s records. A family representative confirmed his death, asking for privacy during this challenging time.

Understanding Recovery Risks

The official cause of Presley Gerber’s death hasn’t been confirmed. Audio from a police dispatch suggested a potential overdose was involved. An autopsy has been completed, but further testing is needed to determine the exact cause.

Gerber was open about his struggles with substance use and mental health. Nicholas Kardaris, Ph.D., CEO of the New York Center for Living and a clinical professor at Stony Brook Medicine, provided insights into what families should know about relapse, overdose risks, and seeking help.

While in treatment, the aim is to create a controlled environment; Kardaris emphasized that addiction treatments do not guarantee resolution of issues or immunity from danger. Facilities strive to prevent substances from entering, but this is not foolproof.

The Dangers of Withdrawal

Withdrawal during rehab can range from uncomfortable to life-threatening. Kardaris highlighted that withdrawal from benzodiazepines and alcohol, without supervision, poses the greatest danger. These can cause seizures and other severe complications.

For opioids, while withdrawal can be distressing, it’s typically not fatal. Cardiovascular events can also occur if there are undisclosed health vulnerabilities.

After detox, the risk of overdose increases because a person’s tolerance decreases, potentially leading to fatal consequences if they resume previous drug doses.

Considering Alternative Treatments

Presley Gerber had shared about undergoing ibogaine treatment in Mexico. While studied for its potential in treating opioid addiction, ibogaine isn’t FDA-approved in the U.S., and its efficacy and safety remain uncertain. Kardaris noted that ibogaine falls into a category with other unregulated psychedelic treatments like ketamine and ayahuasca, which have piqued public interest despite limited regulatory oversight.

Choosing a Treatment Program

Kardaris advises that families should thoroughly investigate treatment centers before registration. It’s crucial to ensure the presence of qualified medical staff and appropriate protocols for handling withdrawals, medication, and emergencies.

A reputable facility with a strong reputation and licensed professionals is pivotal. Families must be cautious of programs that lack these qualifications.